Combining traditional agents and biologics for the treatment of psoriasis

Seminars in Cutaneous Medicine and Surgery

Volumn 24, Issue 1, 2005, Pages 37-45

  Cather, Jennifer Clay ^a   Menter, Alan ^a,b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANALGESIC AGENT; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLOROQUINE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; GLUCOCORTICOID; GOLD; HYDROXYCHLOROQUINE; HYDROXYUREA; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PSORALEN; RETINOID; SALAZOSULFAPYRIDINE; SALICYLIC ACID; TIOGUANINE; UNINDEXED DRUG;

AUTOIMMUNE DISEASE; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CARCINOGENICITY; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DEMYELINATING DISEASE; DISEASE CONTROL; DISEASE EXACERBATION; DRUG SAFETY; ENZYME BLOOD LEVEL; HEADACHE; HEPATITIS B VIRUS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOTOXICITY; INFECTION; INFLAMMATION; LEUKOPENIA; LIVER TOXICITY; LONG TERM CARE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NEOPLASM; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PHARYNGITIS; PHOTOCHEMOTHERAPY; PNEUMONIA; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINUSITIS; TERATOGENICITY; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ACITRETIN; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; CLINICAL TRIALS; CYCLOSPORINE; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; METHOTREXATE; PSORIASIS; PUVA THERAPY; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS;

EID: 15744398663     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2005.01.002     Document Type: Review

References (58)

1. W.H. Boehncke Immunomodulatory drugs for psoriasis BMJ 327 2003 634 635
2. C.E. Griffiths, C.M. Clark, R.J. Chalmers A systematic review of treatments for severe psoriasis Health Technol Assess 4 2000 1 125
3. V.M. Heydendael, P.I. Spuls, B.C. Opmeer Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis N Engl J Med 349 2003 658 665
4. A. Spadaro, V. Riccieri, A. Sili-Scavalli Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis A one-year prospective study Clin Exp Rheumatol 13 1995 589 593
5. H. Gollnick, R. Bauer, C. Brindley Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study J Am Acad Dermatol 19 1988 458 468
6. K. Kragballe, C.T. Jansen, J.M. Geiger A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study Acta Derm Venereol 69 1989 35 40
7. H. Lorenz, J.R. Kalden Biological drugs in rheumatoid arthritis BioDrugs 9 4 1998 303 324
8. G.D. Weinstein, G.M. White An approach to the treatment of moderate to severe psoriasis with rotational therapy J Am Acad Dermatol 28 1993 454 459
9. C.F. Paul, V.C. Ho, C. McGeown Risk of malignancies in psoriasis patients treated with cyclosporine A 5 y cohort study J Invest Dermatol 120 2003 211 216
10. M. Lebwohl, L. Drake, A. Menter Consensus conference Acitretin in combination with UVB or PUVA in the treatment of psoriasis J Am Acad Dermatol 45 2001 544 553
11. M. Lebwohl, C. Tannis, D. Carrasco Acitretin suppression of squamous cell carcinoma case report and literature review J Dermatolog Treat 14 suppl 2 2003 3 6
12. J. Koo Systemic sequential therapy of psoriasis a new paradigm for improved therapeutic results J Am Acad Dermatol 41 1999 S25 S28
13. M.A. Menter, J.A. See, W.J. Amend Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994 J Am Acad Dermatol 34 1996 315 321
14. M. Lebwohl Combining the new biologic agents with our current psoriasis armamentarium J Am Acad Dermatol 49 suppl 2 2003 S118 S124
15. M. Lebwohl New developments in the treatment of psoriasis Arch Dermatol 138 2002 686 688
16. W.G. Stebbins, M.G. Lebwohl Biologics in combination with nonbiologics Efficacy and safety Dermatol Ther 17 2004 432 440
17. M.C. Hochberg, J.K. Tracy, M. Hawkins-Holt Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis Ann Rheum Dis 62 suppl 2 2003 ii13 ii16 Review
18. B.E. Strober, S. Clarke Etanercept for the treatment of psoriasis combination therapy with other modalities J Drugs Dermatol 3 2004 270 272
19. L. Klareskog, D. van der Heijde, J.P. de Jager Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis double-blind randomised controlled trial Lancet 363 2004 675 681
20. M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst A trial of etanercept, a recombinant tumor necrosis factor receptor Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 340 1999 253 259
21. K. Peterson, R. Leff, G. Pausen Etanercept in combination with sulfasalazine (SSA), hydroxychloroquine (HCQ), or gold in the treatment of rheumatoid arthritis (RA) Arthritis Rheum 48 Suppl 9 2003 S324
22. C. Condreanu Double-blind comparison of etanercept and sulfaslazine, alone and combined in RA patients 2003 (Poster). June 19; Lisbon, Portugal
23. R.N. Maini, F.C. Breedveld, J.R. Kalden Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis Arthritis Rheum 41 1998 1552 1563
24. P.E. Lipsky, D.M. van der Heijde, E.W. St Clair Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N Engl J Med 343 2000 1594 1602
25. R.N. Maini, F.C. Breedveld, J.R. Kalden Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate Arthritis Rheum 50 2004 1051 1065
26. T.I. Temekonidis, A.N. Georgiadis, Y. Alamanos Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis Ann Rheum Dis 61 2002 822 825
27. G.F. Ferraccioli, R. Assaloni, E. Di Poi Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate results of an open trial Rheumatology (Oxford) 41 2002 1109 1112
28. K.E. Hansen, J. Cush, A. Singhal The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis Arthritis Rheum 51 2004 228 232
29. P.D. Kiely, D.M. Johnson Infliximab and leflunomide combination therapy in rheumatoid arthritis an open-label study Rheumatology (Oxford) 41 2002 631 637
30. F. Godinho, B. Godfrin, S. El Mahou Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis Clin Exp Rheumatol 22 2004 328 330
31. J.P. Kaltwasser, P. Nash, D. Gladman Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis A multinational, double-blind, randomized, placebo-controlled clinical trial Arthritis Rheum 50 2004 1939 1950
32. G.P. Thami, G. Garg Leflunomide in psoriasis and psoriatic arthritis A preliminary study Arch Dermatol 140 2004 1288 1289
33. R. Rau Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis the initial results of five trials Ann Rheum Dis 61 suppl 2 2002 ii70 ii73
34. J. Kempeni Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7 Ann Rheum Dis 58 suppl 1 1999 I70 I72
35. J. Kempeni Update on D2E7 A fully human anti-tumour necrosis factor alpha monoclonal antibody Ann Rheum Dis 59 suppl 1 2000 i44 i45
36. P. Barrera, L.A. Joosten, A.A. den Broeder Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis Ann Rheum Dis 60 2001 660 669
37. A.A. den Broeder, L.A. Joosten, T. Saxne Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis Effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation Ann Rheum Dis 61 2002 311 318
38. D.E. Furst, M.H. Schiff, R.M. Fleischmann Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) J Rheumatol 30 2003 2563 2571
39. M.H. Schiff, M. Weisman Adalimumab (Humira) plus methatrexate in patients with rheumatoid arthritis continued efficacy up to 4 years in open-label trial 2004 (Poster). June 9-12; Berlin, Germany
40. F.C. Breedveld, R. Rau Long term remission, efficacy and safety in patients with rheumatoid arthritis treated with Adalimumab (Humira) plus methatrexate for more that 5 years 2004 June 9-12; Berlin, Germany
41. M.A. Schneider, H.D. Stahl, T. Podrebarac Tolerability and safety of combination methotrexate and alefacept in rheumatoid arthritis Results of a pilot study 2004 Feb. 6-11; Washington, DC
42. B.E. Strober Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab Arch Dermatol 140 2004 366
43. A.L. Ogilvie, C. Antoni, C. Dechant Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate Br J Dermatol 144 2001 587 589
44. B. Kirby, A.M. Marsland, A.J. Carmichael Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate Clin Exp Dermatol 26 2001 27 29
45. C. Barland, F.A. Kerdel Addition of low-dose methotrexate to infliximab in the treatment of a patient with severe, recalcitrant pustular psoriasis Arch Dermatol 139 2003 949 950
46. J.E. Gach, J. Berth-Jones Successful treatment of recalcitrant psoriasis with a combination of infliximab and hydroxyurea J Dermatolog Treat 14 2003 226 228
47. V.J. Bray, J.E. Huffstutter, S. Schwartzman Emerging role of infliximab (remicade) in psoriatic arthritis patients resistant to disease-modifying antirheumatic drugs case studies 2001 November 10-15, 2001; San Francisco, California
48. D. Gladman, E.C. Keystone, A.B. Gottieb Alefacept in Combination with methotrexate for treatment of active psoriatic arthritis rationale and design of a randomized, double-blind, placebo-controlled study 2004 Feb. 6-11; Washington, DC
49. J. Koo Combination therapy with alefacept plus narrowband ultraviolet B light for treatment of psoriasis 2003 June 18-22; New York, New York
50. J.P. Ortonne, A. Khemis A combination therapy with alefacept plus broadband ultraviolet B light treatment of psoriasis 2003 June 18-22; New York, New York
51. G.G. Krueger, van de Kerkhof P.C. Safety of multiple courses of alefacept in combination with other psoriasis therapies A study that reflects the clinical practice setting 2004 February 6-11; Washington, DC
52. M.A. Menter, W. Abramovits, J.C. Cather Alefacept in combination with tapering doses of methotrexate in patients with psoriasis 2004 February 6-11; Washington, DC
53. M. Magliocco, A. Lozano, C. Kipnis Transitioning patients with psoriasis from cyclosporine to alefacept therapy Results of an open label study 2004 July 28-Aug 1, 2004; New York, New York
54. L.W. Moreland Drugs that block tumour necrosis factor experience in patients with rheumatoid arthritis Pharmacoeconomics 22 suppl 2 2004 39 53
55. R.M. Fleischmann, I. Iqbal, R.L. Stern Considerations with the use of biological therapy in the treatment of rheumatoid arthritis Expert Opin Drug Saf 3 2004 391 403
56. J.M. van der Klooster, R.J. Bosman, H.M. Oudemans-van Straaten Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate Intensive Care Med 29 2003 2327 2329
57. P. Wiland, A. Wiela-Hojenska, A. Glowska Renal function in rheumatoid arthritis patients treated with methotrexate and infliximab Clin Exp Rheumatol 22 2004 469 472
58. E. Mahe, V. Descamps, M. Grossin CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab Br J Dermatol 149 2003 170 173